Key result
In patients with spinal muscular atrophy and 4 SMN2 copies, the risk of losing ambulation was significantly lower for those with type IIIb (HR 0.26) and type IV (HR 0.08) compared to type IIIa.
Why the study?
The study was conducted to provide an overview of the clinical phenotypes associated with four SMN2 copies in pediatric and adult patients.
Observational (n=169)
Yes
Hazard Ratio: 0.26 (95% CI 0.14–0.48)
p-value: p=<0.0001
Patients with SMA and 4 SMN2 copies exhibit highly variable phenotypes, with a significant proportion losing ambulation over time, challenging the assumption that they are all stable.
Phenotypes vary widely in SMA with 4 SMN2 copies; leaves open optimal prognostic stratification and trial eligibility criteria.
OBJECTIVE: The aim of this study was to provide an overview of the clinical phenotypes associated with 4 SMN2 copies. METHODS: Clinical phenotypes were analyzed in all the patients with 4 SMN2 copies as part of a nationwide effort including all the Italian pediatric and adult reference centers for spinal muscular atrophy (SMA). RESULTS: The cohort includes 169 patients (102 men and 67 women) with confirmed 4 SMN2 copies (mean age at last follow-up = 36.9 ± 19 years). Six of the 169 patients were presymptomatic, 8 were classified as type II, 145 as type III (38 type IIIA and 107 type IIIB), and 8 as type IV. The remaining 2 patients were asymptomatic adults identified because of a familial case. The cross-sectional functional data showed a reduction of scores with increasing age. Over 35% of the type III and 25% of the type IV lost ambulation (mean age = 26.8 years ± 16.3 SD). The risk of loss of ambulation was significantly associated with SMA type (p < 0.0001), with patients with IIIB and IV less likely to lose ambulation compared to type IIIA. There was an overall gender effect with a smaller number of women and a lower risk for women to lose ambulation. This was significant in the adult (p = 0.009) but not in the pediatric cohort (p = 0.43). INTERPRETATION: Our results expand the existing literature on natural history of 4 SMN2 copies confirming the variability of phenotypes in untreated patients, ranging from type II to type IV and an overall reduction of functional scores with increasing age. ANN NEUROL 2023;94:1126-1135.
No takes yet. Share an insight, caveat, or question.
Ricci et al. (2023) conducted an observational in Spinal Muscular Atrophy with 4 SMN2 copies (n=169). SMA type IIIb vs. SMA type IIIa was evaluated on Loss of ambulation (HR 0.26, 95% CI 0.14-0.48, p=<0.0001). In patients with spinal muscular atrophy and 4 SMN2 copies, the risk of losing ambulation was significantly lower for those with type IIIb (HR 0.26) and type IV (HR 0.08) compared to type IIIa.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: